La Jolla Pharmaceutical Company - Product Pipeline Review - 2016 - Global Markets Direct - Market Research

La Jolla Pharmaceutical Company - Product Pipeline Review - 2016

La Jolla Pharmaceutical Company - Product Pipeline Review - 2016 - Global Markets Direct - Market Research
La Jolla Pharmaceutical Company - Product Pipeline Review - 2016
Published Jun 22, 2016
39 pages — Published Jun 22, 2016
Price US$ 1,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, La Jolla Pharmaceutical Company - Product Pipeline Review - 2016, provides an overview of the La Jolla Pharmaceutical Companys pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by La Jolla Pharmaceutical Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of La Jolla Pharmaceutical Company
- The report provides overview of La Jolla Pharmaceutical Company including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses La Jolla Pharmaceutical Companys pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features La Jolla Pharmaceutical Companys out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate La Jolla Pharmaceutical Companys strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for La Jolla Pharmaceutical Company
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding La Jolla Pharmaceutical Companys pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and exp

  
Source:
Document ID
GMDHC08071CDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
La Jolla Pharmaceutical Company Snapshot51
  La Jolla Pharmaceutical Company Overview51
  Key Information51
  Key Facts51
La Jolla Pharmaceutical Company Research and Development Overview63
  Key Therapeutic Areas63
La Jolla Pharmaceutical Company Pipeline Review92
  Pipeline Products by Stage of Development91
  Pipeline Products Monotherapy101
La Jolla Pharmaceutical Company Pipeline Products Glance115
  La Jolla Pharmaceutical Company Late Stage Pipeline Products111
    Phase III Products/Combination Treatment Modalities111
  La Jolla Pharmaceutical Company Clinical Stage Pipeline Products121
    Phase I Products/Combination Treatment Modalities121
  La Jolla Pharmaceutical Company Early Stage Pipeline Products131
    Preclinical Products/Combination Treatment Modalities131
    Discovery Products/Combination Treatment Modalities141
  La Jolla Pharmaceutical Company - Unknown Stage Pipeline Products151
    Unknown Products/Combination Treatment Modalities151
La Jolla Pharmaceutical Company Drug Profiles1610
  LJPC-501161
    Product Description161
    Mechanism of Action161
    R&D Progress161
  LJPC-401171
    Product Description171
    Mechanism of Action171
    R&D Progress171
  LJPC-0712181
    Product Description181
    Mechanism of Action181
    R&D Progress181
  LJPC-30Sa191
    Product Description191
    Mechanism of Action191
    R&D Progress191
  LJPC-30Sb201
    Product Description201
    Mechanism of Action201
    R&D Progress201
  LJPC-6417211
    Product Description211
    Mechanism of Action211
    R&D Progress211
  Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva221
    Product Description221
    Mechanism of Action221
    R&D Progress221
  Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva231
    Product Description231
    Mechanism of Action231
    R&D Progress231
  Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders241
    Product Description241
    Mechanism of Action241
    R&D Progress241
  Drugs for Undisclosed Indications251
    Product Description251
    Mechanism of Action251
    R&D Progress251
La Jolla Pharmaceutical Company Pipeline Analysis264
  La Jolla Pharmaceutical Company Pipeline Products by Target261
  La Jolla Pharmaceutical Company Pipeline Products by Route of Administration271
  La Jolla Pharmaceutical Company Pipeline Products by Molecule Type281
  La Jolla Pharmaceutical Company Pipeline Products by Mechanism of Action291
La Jolla Pharmaceutical Company Recent Pipeline Updates303
La Jolla Pharmaceutical Company Dormant Projects331
La Jolla Pharmaceutical Company Discontinued Pipeline Products341
  Discontinued Pipeline Product Profiles341
    GCS-100341
    LJPC-1010341
La Jolla Pharmaceutical Company Company Statement352
La Jolla Pharmaceutical Company Locations And Subsidiaries371
  Head Office371
  Other Locations &Subsidiaries371
Appendix382
  Methodology381
  Coverage381
  Secondary Research381
  Primary Research381
  Expert Panel Validation381
  Contact Us381
  Disclaimer391

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "La Jolla Pharmaceutical Company - Product Pipeline Review - 2016" Jun 22, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/La-Jolla-Pharmaceutical-Company-Product-Pipeline-Review-2016-2088-15987>
  
APA:
Global Markets Direct - Market Research. (2016). La Jolla Pharmaceutical Company - Product Pipeline Review - 2016 Jun 22, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/La-Jolla-Pharmaceutical-Company-Product-Pipeline-Review-2016-2088-15987>
  
US$ 1,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.